• Treat CoreWeave (CRWV) as a high-risk, volatile investment: its sharp drop reflected debt and financing concerns, and any NVIDIA (NVDA) or Oracle (ORCL) backstop remains speculation.
• Avoid trading SanDisk (SNDK) or Micron (MU) solely on the selloff reversal; the transcript flags a possible memory glut and offers no confirmed earnings-based catalyst or price target.
• No other names have a sufficiently clear, supported trade thesis here; ignore the staged deal rumors and simulated trades as investment signals.

Anthropic (Private)

• The speaker said Anthropic reported $16.8 billion in revenue versus a Street expectation of $18 billion, despite roughly 50% quarter-on-quarter growth.
• He also cited a $110 billion year-end run rate and illustrated a valuation of about $2.2 trillion using a 20× multiple. That was back-of-the-envelope arithmetic, not a stated price target.
• The discussion was mixed: the growth was described as exceptional, but the speaker noted that such rapid growth will eventually slow and that investors’ expectations may be difficult to satisfy.

Takeaways

• The main issue raised was not weak growth, but whether expectations have become too demanding. Anthropic is private, so the transcript does not identify a publicly traded stock to buy.

OpenAI (Private)

• OpenAI was contrasted with Anthropic as more deliberate about revenue growth. The speaker compared that approach with Google’s earlier, steadier growth.

Takeaways

• The discussion frames a trade-off between pursuing rapid growth and building revenue more gradually. No specific investment recommendation or valuation was given.

NVIDIA (NVDA)

• NVIDIA shares were repeatedly described as falling during a broad selloff in semiconductor and AI-related stocks, then recovering somewhat.
• The speaker argued that NVIDIA might need to support CoreWeave for the AI infrastructure rally to continue, at one point speculating about a $10 billion check. Later, he acknowledged that a bailout was not clearly necessary and that NVIDIA’s comments about CoreWeave should be viewed in light of its relationship with the company.
• The transcript also contains a staged trading skit involving alleged undisclosed NVIDIA and TSM deal information. The speaker later said it was a joke; it should not be treated as a real catalyst or trading signal.

Takeaways

• The discussion highlights NVIDIA’s exposure to customer and financing concerns across AI infrastructure—not just demand for its chips. Treat the supposed deal announcement in the skit as unverified and not actionable.

CoreWeave (CRWV)

• CoreWeave was a central focus during the market selloff. Its share price was described as falling from around $100 to below $60, then rebounding toward the upper $60s.
• The speaker called the company vulnerable to investor fears about debt and potential default, while noting that CoreWeave said it had no immediate troubles. He also discussed its bonds trading around 79–80 cents on the dollar, while cautioning that the quoted bond prices might be stale.
• A possible NVIDIA or Oracle rescue was discussed as speculation, not a confirmed plan. The speaker said that even a rescue might not resolve concerns about the company’s debt and future obligations.

Takeaways

• The transcript presents CoreWeave as a high-risk, high-volatility AI infrastructure investment, with financing and debt concerns central to the debate. The proposed backstops were speculative, not recommendations or confirmed developments.

Micron (MU), SanDisk (SNDK) and Memory Stocks

• Micron and SanDisk fell during the semiconductor selloff. The speaker noted concerns that China could produce more memory and that a memory glut might emerge.
• The discussion also described a sharp, broad reversal in memory and semiconductor shares. A short position in SanDisk was mentioned, followed by the speaker’s view that the panic might be bullish and that the shares could be a buy ahead of earnings—but he cautioned that this view might be early.
• A trading demo showed activity in SanDisk and Micron. These were presented as demo trades, not a formal investment recommendation.

Takeaways

• The key issue is whether memory demand and AI-related compute needs will remain strong enough to absorb new supply. The transcript gives both sides of the debate and does not establish that a memory glut will occur.

AMD (AMD) and Intel (INTC)

• Both stocks fell during the selloff. The speaker criticized AMD’s GPUs relative to NVIDIA’s, while noting that AMD’s CPUs are used.
• Intel was also described as under pressure, though the transcript later includes a demo trade that covered a short position in Intel. The demo entries should not be read as a recommendation.

Takeaways

• The discussion reflects concerns about semiconductor competition and market volatility, not a detailed company-specific valuation thesis. No price targets or long-term outlooks were given.

Other Semiconductor and Hardware Stocks

• ASML (ASML), Broadcom (AVGO), Marvell (MRVL), Lumentum (LITE), Dell (DELL), Kioxia (285A), Qualcomm (QCOM), KLA (KLAC) and Applied Materials (AMAT) were mentioned amid broad declines, rebounds or demo trading.
• The speaker described the wider semiconductor and AI infrastructure trade as under pressure. Later orders in several of these names appeared within an explicitly simulated trading interface, without supporting investment theses.
• The transcript mentions “Taiwan” falling despite strong results and later includes a staged TSM deal rumor. It does not clearly establish the former reference as a specific company, and the latter was part of a joke—not verified news.

Takeaways

• These mentions mostly illustrate sector-wide volatility rather than differentiated views on individual companies. The transcript does not provide enough company-specific analysis to support a trade in these names.

Twist Bioscience (TWST)

• The speaker said Twist had grown steadily for years and described its shares as difficult to short. He considered the stock expensive at earlier levels around $160–$200, but said he was unsure it was the right short at roughly $140.

Takeaways

• The speaker’s comments were cautious about shorting a steadily growing company, even when he considered its valuation high. No buy recommendation or price target was given.

10x Genomics (TXG) and Ginkgo Bioworks (DNA)

• The speaker suggested TXG and Ginkgo as possible alternatives to shorting Twist. He described Ginkgo in strongly negative terms, but gave no detailed financial or operating evidence in the transcript.

Takeaways

• These were speculative short ideas, not fully developed theses. The transcript provides no price targets, catalysts or risk analysis to support acting on them.

Quantum Stocks: D-Wave (QBTS), Rigetti (RGTI) and IonQ (IONQ)

• The three stocks were described as down during the market selloff. The speaker characterized quantum names as high beta, meaning they can move sharply with market sentiment.
• He also said Jensen Huang is generally bearish on quantum computing, while acknowledging he did not know whether Huang had made a new comment about the sector.

Takeaways

• The transcript emphasizes volatility and uncertain sentiment, not a specific view on which quantum company is best positioned. No individual company thesis or valuation was offered.

Moderna (MRNA) and Biohaven (BHVN)

• Moderna was described as rallying strongly, but the speaker said it was hard to know whether the rally would continue and expressed uncertainty about an upcoming Phase 3 disclosure.
• Biohaven was mentioned in connection with upcoming obesity data, which the speaker thought might involve a myostatin program.

Takeaways

• The discussion points to clinical data as a potential catalyst, but offers no result expectations, timelines beyond the reference to upcoming data, or investment recommendation. Trial outcomes can materially affect biotech shares.

Other Pharma and Biotech Names

• A response in the transcript suggested Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK), Amgen (AMGN) and Vertex (VRTX) as large-cap pharma names to examine.
• It also named Alnylam (ALNY), Agios (AGIO), Ultragenyx (RARE), Agenus (AGEN) and BioCryst (BCRX) as higher-beta biotech examples. The transcript includes demo trades in Lilly, Merck and Pfizer (PFE), but does not give investment theses for those positions.
• The same response suggested focusing on clinical readouts, FDA decisions and cash runway. These were general diligence considerations, not company-specific conclusions.

Takeaways

• The names were offered as a watchlist, not as buy recommendations. The transcript does not compare their valuations, products or financial positions.

Bitcoin (BTC)

• The speaker said he was not yet sure he was bullish on Bitcoin. A price around $64,000 was mentioned, but no target or forecast was provided.

Takeaways

• The transcript offers an explicitly uncertain view and no actionable entry point or price target.

Other Market and Investment Themes

• The speaker said the market reminded him of the 1999–2000 period only after citing Paul Tudor Jones’s warning about similarities. The speaker disagreed, saying he did not see the same setup.
• He described a possible move into biotech during the selloff and discussed the possibility that investors might question how much capital is being spent on AI compute.
• Oracle (ORCL) was described as potentially being able to support CoreWeave, but this was speculation. Walmart (WMT) rose during the session and was characterized as part of a rotation into the stock.
• Meta (META), Alphabet/Google (GOOGL), Microsoft (MSFT), Apple (AAPL), Salesforce (CRM), Palantir (PLTR), SpaceX, and other technology names were mentioned mainly in market updates. SpaceX was described as private; the transcript’s later claims about a public ticker were contradictory and unreliable.

Takeaways

• The discussion highlights a potential shift away from crowded AI and semiconductor trades, but it does not establish a durable rotation or a market-wide bubble. The speaker’s comments and intraday price moves are not, on their own, investment signals.

Additional Stocks Mentioned in the Trading Demo

• The simulated blotter also included TJX (TJX), Costco (COST), Nike (NKE), Coca-Cola (KO), Disney (DIS), Johnson & Johnson (JNJ), PepsiCo (PEP), Chevron (CVX), Thermo Fisher (TMO), Pfizer (PFE), Illumina (ILMN), Vaxcyte (PCVX) and Microsoft (MSFT).
• The transcript showed sample buys, shorts and position updates, but did not provide substantive company analysis for most of these names. The trading interface also showed an unusually wide SMH quote and a costly short-and-cover sequence, which the speaker acknowledged was a bad fill.
• SPY, QQQ and XLK were mentioned as possible broad-market or technology hedges; SMH was used as a semiconductor hedge. The transcript noted that a portfolio can be dollar-neutral without being beta-neutral.

Takeaways

• Treat the orders and P&L figures in this section as simulated trading activity, not recommendations. The SMH episode illustrates the execution risk of trading a security when displayed bid–ask prices are unusually wide.